SynthesisFrontiers in physiology2026
Continuous aerobic exercise and atherosclerosis-related vascular indices in overweight and obese adults: a Bayesian three-level meta-analysis of randomized controlled trials.
Synthesis in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Overweight and obesity accelerate vascular aging and atherosclerosis-related processes through endothelial dysfunction and increased arterial stiffness. Whether continuous endurance training (CET) improves key vascular functional and structural indices in overweight/obese adults remains uncertain, and evidence synthesis is complicated by correlated effect sizes within trials. Objective: To quantify the effects of CET on flow-mediated dilation (FMD), pulse wave velocity (PWV), and carotid intima-media thickness (CIMT) in overweight and obese adults using a Bayesian three-level meta-analysis of randomized controlled trials (RCTs). Methods: PubMed, Web of Science, Cochrane Library, Embase, APA PsycINFO, and EBSCO-SportDiscus were searched from inception to November 2025. Eligible studies were RCTs enrolling adults (18-65 years) with overweight/obesity, comparing CET with usual care/usual lifestyle, and reporting baseline and post-intervention data for FMD, PWV, or CIMT (≥4 weeks). Standardized mean differences (SMDs) for between-group changes were synthesized using a Bayesian three-level random-effects model to account for within-study dependency. Risk of bias was assessed with RoB 2, and certainty of evidence with GRADE. Results: Seventeen RCTs (746 participants) were included. CET improved FMD (13 studies, 14 effect sizes; μ = 1.14, 95% credible interval [CrI] 0.42 to 1.95), with substantial between-study heterogeneity. CET reduced PWV (7 studies, 9 effect sizes; μ = -0.23, 95% CrI -0.41 to -0.06) with minimal heterogeneity, indicating a consistent benefit on arterial stiffness. The effect on CIMT was not conclusive (5 studies, 5 effect sizes; μ = -0.23, 95% CrI -0.66 to 0.18). Exploratory subgroup analyses suggested the most consistent improvements clustered around interventions lasting 9-12 weeks and performed three sessions per week. GRADE certainty was low for FMD, moderate for PWV, and very low for CIMT, mainly due to risk of bias and imprecision. Conclusions: In overweight and obese adults, CET yields a "function-first" vascular response-improving endothelial function (FMD) and reducing arterial stiffness (PWV)-while evidence for short- to mid-term structural change in CIMT remains insufficient. Future well-designed RCTs with longer follow-up and standardized vascular assessments are needed to clarify CET effects on vascular remodeling. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42024593701.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.